2025 -  WEEK 25

What's New in RWE Research this Week

  1. Developing a Coordinated Registry Network for devices used for acute ischemic stroke intervention: basilar artery occlusion quality assessment pilot. Mao J, Ansari SA, Siddiqui AH, Sedrakyan A, Marinac-Dabic D, Sheldon M, Claffey M, Hall AM, Sancheti H, Kim T, Nguyen N, Liebeskind DS.J Neurointerv Surg. 2025 Jun 16;17(7):691-696. doi: 10.1136/jnis-2024-021741.PMID: 38862209 Free PMC article.

 

  1. Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity Planning.Kadambi A, Krekels EHJ, Martinecz A, Fatzinger G, Jones HM, Khachatryan A, Yeo KR, Brown F.Clin Transl Sci. 2025 Jun;18(6):e70276. doi: 10.1111/cts.70276.PMID: 40525392 Free PMC article.

 

  1. The Use of Machine Learning for Analyzing Real-World Data in Disease Prediction and Management: Systematic Review. Alhumaidi NH, Dermawan D, Kamaruzaman HF, Alotaiq N. JMIR Med Inform. 2025 Jun 19;13:e68898. doi: 10.2196/68898. PMID: 40537090

 

  1. Therapy-related myeloid neoplasms in 177Lu-DOTATATE treated neuroendocrine tumor patients: how great is the risk? Kusne Y, Patnaik MM, Halfdanarson TR, Sonbol MB.Endocr Relat Cancer. 2025 Jun 16;32(6):e250025. doi: 10.1530/ERC-25-0025. Print 2025 Jun 1.PMID: 40446156 Review.

 

  1. Methodological approaches in the economic evaluation of prognostic and predictive Companion diagnostics: a systematic scoping review. Hakkarainen T, Ira H, Riikka-Leena L.Expert Rev Pharmacoecon Outcomes Res. 2025 Jun 16. doi: 10.1080/14737167.2025.2519744. Online ahead of print.PMID: 40518839 Review.

 

  1. Assessing the effectiveness of camrelizumab plus anti-angiogenesis drug for the treatment of advanced liver cancer: a single‑center retrospective study. Lu F, Wu F.Immunopharmacol Immunotoxicol. 2025 Jun 16:1-8. doi: 10.1080/08923973.2025.2513481. Online ahead of print.PMID: 40521632

 

  1. Impact of Complete Revascularization Strategies on the Clinical Outcomes of Patients With Non-ST-Segment Elevation Myocardial Infarction and Multivessel Disease: Multicentre Real-World Evidence From China. Rao C, Zhong Q, Li Z, Fu L, Liu W, Qin W, Gao J, Liu B, He K, Zhou F.Catheter Cardiovasc Interv. 2025 Jun 16. doi: 10.1002/ccd.31679. Online ahead of print.PMID: 40521697

 

  1. The Terumo Aortic Global Endovascular Registry: A Multiarm, Multicenter, Open Label, Prospective Observational Registry to Obtain Safety and Performance Data on off-the-Shelf and Custom-Made Stent-Grafts. Reijnen MMPJ, Rylski B, Millon A, Geelkerken RH, Hyhlik-Dürr A, Hoksbergen AWJ, Veroux P, Weigang E, Tessarek J, Riambau V.J Endovasc Ther. 2025 Jun 16:15266028251344790. doi: 10.1177/15266028251344790. Online ahead of print.PMID: 40521921

 

  1. Biologics targeting IL-23 in moderate-to-severe psoriasis: lessons learned from real-world use. Megna M, Lauletta G, D'Agostino M, Tommasino N, Salsano A, Noto M, Brescia C, Foggia L, Scaramuzzino L, Potestio L.Expert Opin Biol Ther. 2025 Jun 16. doi: 10.1080/14712598.2025.2519525. Online ahead of print.PMID: 40522209 Review.

 

  1. Predicting mucosal healing in Crohn's disease: development of a deep-learning model based on intestinal ultrasound images. Ma L, Chen Y, Fu X, Qin J, Luo Y, Gao Y, Li W, Xiao M, Cao Z, Shi J, Zhu Q, Guo C, Wu J.Insights Imaging. 2025 Jun 16;16(1):125. doi: 10.1186/s13244-025-02014-5.PMID: 40522531 Free PMC article.

 

  1. Comparative Effectiveness of Fumarates Versus Sphingosine-1-Phosphate Receptor Modulators in Black Patients with Multiple Sclerosis. Woodson S, Gettings EJ, Guo CY, Klineova S, Lee JM, Romero RS, Walker A, Belviso N, Shankar SL, Mendoza JP, Bian B, Lewin JB, Fong K.Neurol Ther. 2025 Jun 16. doi: 10.1007/s40120-025-00774-2. Online ahead of print.PMID: 40522622

 

  1. Real-World Analysis of Healthcare Utilization, Treatment Patterns, and Economic Burden in Medicare Beneficiaries with Parkinson's Disease: Implications by Levodopa Formulation and Disease Severity. Arnold RJG, Tse W, Martin K, Kuan R.Pharmacoecon Open. 2025 Jun 16. doi: 10.1007/s41669-025-00588-w. Online ahead of print.PMID: 40524136

 

  1. Preliminary Report on the Efficacy and Safety of Triplet Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer: YUSHIMA Study. Yasuda Y, Numao N, Matsumoto S, Tamiya T, Nakamura Y, Tanaka H, Yoshida S, Kobayashi S, Takazawa R, Matsuoka Y, Yonese J, Fujii Y.Int J Urol. 2025 Jun 16. doi: 10.1111/iju.70154. Online ahead of print.PMID: 40524477

 

  1. Cardiac troponin at the point of care in acute and chronic coronary syndromes. McDermott M, Tew YY, Cooper JG, Harry D, Mills NL.Diabetes Obes Metab. 2025 Jun 16. doi: 10.1111/dom.16503. Online ahead of print.PMID: 40524517

 

  1. Lansoprazole identified as a prophylactic agent for oxaliplatin-induced peripheral neuropathy using integrated in silico, in vitro, and in vivo analyses. Kobayashi A, Ikemura K, Ueno M, Wakai E, Yamane F, Okuda M.Biomed Pharmacother. 2025 Jun 16;189:118272. doi: 10.1016/j.biopha.2025.118272. Online ahead of print.PMID: 40527038

 

  1. Prospective observational study of tofacitinib in ulcerative colitis - analysis of clinical data, fatigue and health-related quality of life during the induction phase. Nyberg L, Halfvarson J, Söderling J, Olén O, Strid H, Hedin CRH, Jónsdóttir SB, Hjortswang H, Jäghult S, Cappelleri JC, Henrohn D, Seddighzadeh M, Marsal J, Grip O; SWIBREG ODEN Study Group.Therap Adv Gastroenterol. 2025 Jun 16;18:17562848251343427. doi: 10.1177/17562848251343427. eCollection 2025.PMID: 40535533 Free PMC article.

 

  1. Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFRExon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED). Ishihara M, Kawamura T, Namba Y, Takeyasu Y, Hasegawa Y, Sato Y, Negi Y, Oba T, Sumi T, Hirata H, Funabashi H, Oya Y, Kikuchi H, Katsurada N, Nakatani T, Tanimura K, Nakagawa T, Takeda N, Asami T, Honjo O, Nagashima H, Yamaura T, Hata N, Kitazono M, Nishioka N, Tamiya A, Sakamori Y, Shigaki R, Kaira K, Honda R, Matsui T, Suzuki E, Ito K, Otsuka K, Takase N, Murakami Y, Matsuno K, Inoue S, Kisohara A, Kusumoto S, Aoshima H, Kakizaki Y, Kubo A, Hata A, Ishikawa N, Hamai K, Kanaji N, Misumi T, Matsutani N, Seki N.Ther Adv Med Oncol. 2025 Jun 16;17:17588359251344010. doi: 10.1177/17588359251344010. eCollection 2025.PMID: 40535732 Free PMC article.

 

  1. Comparative evaluation of behavioral epidemic models using COVID-19 data. Gozzi N, Perra N, Vespignani A.Proc Natl Acad Sci U S A. 2025 Jun 17;122(24):e2421993122. doi: 10.1073/pnas.2421993122. Epub 2025 Jun 12.PMID: 40504146

 

  1. Actions for Stakeholders to Develop Better Real-World Evidence for HTA/Payer Decision-Making. Jaksa AA, Pavel AN, Aapro M, Hedberg N, Hodgkinson V, Lambert LJ, Meyer F, Olsen M, Rannanheimo PK, Facey KM.Int J Technol Assess Health Care. 2025 Jun 17:1-32. doi: 10.1017/S0266462325100238. Online ahead of print.PMID: 40524330 No abstract available.

 

  1. Adverse Effects of Dupilumab for Chronic Rhinosinusitis With Nasal Polyposis: Real-World Single Institution Experience. Wang AJ, Jiang R, Runyan T, Abi Hachem R, Goldstein BJ, Jang DW. 2025 Jun 17. doi: 10.1002/lary.32359. Online ahead of print.PMID: 40525458

 

  1. Perspectives in Perioperative Quality Improvement: Case Studies in Positive Deviance Using Real-World Data. Low AB, Maresh JR, Jarvi T, Esser J, Rawson T, Fernandez N, Chiem JL, Feldman RM, Hale JV, Merguerian PA, Lander TA, Martin LD.Paediatr Anaesth. 2025 Jun 17. doi: 10.1111/pan.15143. Online ahead of print.PMID: 40525583

 

  1. GLP-1 Receptor Agonist Outcomes, Safety, and BMI Change in a National Cohort of Dialysis Patients. Orandi BJ, Chen Y, Li Y, Charyton D, Lentine KL, Lee BP, Ali N, DeMarco MP, Weintraub MA, Bae S, Lonze BE, Ren-Fielding CJ, Lofton H, Gujral A, Segev DL, McAdams-DeMarco M.Clin J Am Soc Nephrol. 2025 Jun 17. doi: 10.2215/CJN.0000000750. Online ahead of print.PMID: 40526425

 

  1. Real-world Evidence of Duvelisib and Romidepsin in Relapsed/Refractory Peripheral and Cutaneous T-cell Lymphomas. Ford J, Koh MJ, Lenart AW, MacVicar CT, Chopra K, Meharwal A, Sorial MN, Merrill MH, Rider AB, Sohani A, McCabe SM, Nemec RA, Iwasaki M, Mistry D, Kariya KM, Chen S, Barnes JA, McAfee S, Chen YB, Wong CY, Nasto K, Jacobsen ED, Jain S.Blood Adv. 2025 Jun 17:bloodadvances.2025016347. doi: 10.1182/bloodadvances.2025016347. Online ahead of print.PMID: 40526834

 

  1. Evaluating the Characteristics and Outcomes of Acute Pharmaceutical Exposure in Children: 5-Year Retrospective Study. Duan ZY, Qu YN, Tang R, Liu JT, Wang H, Sheng MY, Wang LL, Liu S, Li J, Guo LY, Zheng S.JMIR Pediatr Parent. 2025 Jun 17;8:e66951. doi: 10.2196/66951.PMID: 40526889

 

  1. Clinical Outcomes of Patients with SLE Treated with Belimumab, Without Versus With Prior Immunosuppressant Use: a US Claims Database Study. Costenbader KH, DerSarkissian M, Chen Y, Rabideau B, Worley K, Man T, Rubin B, Lim SS.Rheumatol Ther. 2025 Jun 17. doi: 10.1007/s40744-025-00774-6. Online ahead of print.PMID: 40528076

 

  1. Evaluating the Impact of mySugr() Mobile Health Application on Glycemic Control in People with Diabetes Mellitus in India: A Real-World Data Mohan V, Kalra S, Augustine A, Kober J.Diabetes Ther. 2025 Jun 17. doi: 10.1007/s13300-025-01768-x. Online ahead of print.PMID: 40528139

 

  1. Long-Term Use of Tralokinumab in Patients With Atopic Dermatitis: A Real-World Multicentric Case Series. Bangert C, Ebner B, Gruber B, Meyersburg D, Traxler J.Int J Dermatol. 2025 Jun 17. doi: 10.1111/ijd.17913. Online ahead of print.PMID: 40528669 No abstract available.

 

  1. Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancer. Tarantino P, Lee D, Foldi J, Soulos PR, Gross CP, Grinda T, Winer EP, Lin NU, Krop IE, Tolaney SM, Lustberg M, Sammons S.ESMO Open. 2025 Jun 17;10(7):105330. doi: 10.1016/j.esmoop.2025.105330. Online ahead of print.PMID: 40532362 Free article.

 

  1. Real-world clinical outcomes of patients with moderate-to-severe rheumatoid arthritis initiating upadacitinib in the United Kingdom: Final analysis from a prospective observational cohort study (ENDEAVOUR). Taylor J, Srirangan S, Bukhari M, Bilgrami S, Nisar MK, McDonald S, Goodson N, Allard A, Kinder A, Green M, Hunt L, Raizada S, Kirkham B, Thomas E, Horsfall R, Niblock TL, Burton V, Galloway J.Curr Med Res Opin. 2025 Jun 18:1-17. doi: 10.1080/03007995.2025.2515280. Online ahead of print.PMID: 40528571

 

  1. CTRH as Biomarker of Drug Efficacy: In-Depth Assessment of Real-World Evidence. Khosrow-Khavar F, Kreutz R, Douros A. 2025 Jun 18. doi: 10.1161/HYPERTENSIONAHA.124.24523. Online ahead of print.PMID: 40528750

 

  1. Impact of Transport Method in Patients With ST-Segment-Elevation Myocardial Infarction on Patient Outcomes: Real-World Data From the ACSIS Registry. Rotholz A, Lerman TT, Awesat J, Eisen A, Beigel R, Kanani E, Braver O, Orvin K.J Am Heart Assoc. 2025 Jun 18:e040813. doi: 10.1161/JAHA.124.040813. Online ahead of print.PMID: 40530485

 

  1. Renin-Angiotensin-Aldosterone System Inhibitor Dosing After Initiation of Outpatient Sodium Zirconium Cyclosilicate Therapy: The GALVANIZE RAASi Real-World Evidence Agiro A, Greatsinger A, Mu F, Cook EE, Chen J, Sundar M, Zhao A, Colman E, Malhotra A. Adv Ther. 2025 Jun 18. doi: 10.1007/s12325-025-03254-z. Online ahead of print.PMID: 40531443

 

  1. Glucose Control, Sulfonylureas, and Insulin Treatment in Older Adults With Type 2 Diabetes and Risk of Falls and Fractures: An Observational Study. Shabnam S, Ling S, Gillies C, Zaccardi F, Choudhary P, Khunti K, Seidu S. Diabetes Care. 2025 Jun 18:dc250517. doi: 10.2337/dc25-0517. Online ahead of print.PMID: 40532134

 

  1. Treatment with gemcitabine/cisplatin and durvalumab for advanced biliary tract cancer - real-world data from a multicenter German patient population. Gerhardt F, Müller C, Venerito M, Chater J, Mohr R, Egerer M, Lindig U, Schindler A, Ebel S, Fischer J, Schwarz M, Gehring S, Berg T, van Bömmel F.J Cancer Res Clin Oncol. 2025 Jun 18;151(6):191. doi: 10.1007/s00432-025-06239-1.PMID: 40533571 Free PMC article.

 

  1. Overcoming therapeutic resistance in driver-negative NSCLC: Immunomodulatory mechanisms and clinical efficacy of Camrelizumab-chemotherapy combination in a real-world cohort. Ge Y, Zhao Y.Discov Oncol. 2025 Jun 18;16(1):1148. doi: 10.1007/s12672-025-02926-0.PMID: 40533655 Free PMC article.

 

  1. Real-world Cost per Responder Among Different Classes of Biologics for the Treatment of Psoriasis. Godding LTH, Seyger MMB, Duvetorp A, Otero ME, Ossenkoppele PM, Oostveen AM, Visch MB, Van der Voort EAM, Körver JEM, Weppner-Parren LJMT, Berends MAM, Arnold WP, Dodemont SRP, Kuijpers ALA, Mommers JM, Homan FM, Gostynski AH, Velstra B, Kleinpenning MM, Van Doorn MBA, Keijsers RRMC, Kop EN, Haeck IM, Hendricksen-Roelofzen JHJ, Vellinga D, De Jong EMGJ, Van den Reek JMPA.Acta Derm Venereol. 2025 Jun 18;105:adv42767. doi: 10.2340/actadv.v105.42767.PMID: 40534202

 

  1. Evaluating Patient Adherence and Persistence to Tyrosine-Kinase Inhibitors for Metastatic Renal Cell Carcinoma: A Retrospective Analysis of Real-World Data. Arter ZL, Benjamin DJ, Cao Y, Farias J, Thirumaran RK, Forsyth M, Mar N, Rezazadeh Kalebasty A.Clin Med Insights Oncol. 2025 Jun 18;19:11795549251341877. doi: 10.1177/11795549251341877. eCollection 2025.PMID: 40538886 Free PMC article.

 

  1. The health and economic burden of dengue in Germany: a retrospective analysis of data on statutory health insurance claims. Goodman E, Schneider KM, Lang L, Schnaidt S, Viering T, Greiner W, Jacob C.Infect Dis Now. 2025 Jun 18:105107. doi: 10.1016/j.idnow.2025.105107. Online ahead of print.PMID: 40541700

 

  1. Efficacy and Safety of High-Intensity Statins in Japanese Patients After Percutaneous Coronary Intervention　- Insights From the Clinical Deep Data Accumulation System (CLIDAS®). Matoba T, Katsuki S, Nakano Y, Kawahara T, Kimura M, Hino R, Tabuchi T, Fukata M, Hieda M, Yamashita T, Nakashima N, Kohro T, Kabutoya T, Oba Y, Kario K, Imai Y, Fujita H, Akashi N, Kiyosue A, Mizuno Y, Kodera S, Nakayama M, Nochioka K, Miyamoto Y, Iwai T, Tsujita K, Nakamura T, Ishii M, Sato H, Matoba Y, Nagai R; CLIDAS Research Group.Circ J. 2025 Jun 19. doi: 10.1253/circj.CJ-25-0066. Online ahead of print.PMID: 40533165 Free article.

 

  1. Predicting Early-Onset Colorectal Cancer in Individuals Below Screening Age Using Machine Learning and Real-World Data: Case Control Study. Sun C, Mobley E, Quillen M, Parker M, Daly M, Wang R, Visintin I, Awad Z, Fishe J, Parker A, George T, Bian J, Xu J.JMIR Cancer. 2025 Jun 19;11:e64506. doi: 10.2196/64506.PMID: 40537065

 

  1. The Use of Machine Learning for Analyzing Real-World Data in Disease Prediction and Management: Systematic Review. Alhumaidi NH, Dermawan D, Kamaruzaman HF, Alotaiq N.JMIR Med Inform. 2025 Jun 19;13:e68898. doi: 10.2196/68898.PMID: 40537090 Free article.

 

  1. Prognostic impact of the timing of antihypertensive medication initiation for hypertension detected at health screening on primary prevention of adverse cardiovascular events: Age-stratified real-world data Ito H, Seki T, Kawazoe Y, Takiguchi T, Akagi Y, Kubota K, Miyake K, Okada M, Ohe K.Hypertens Res. 2025 Jun 19. doi: 10.1038/s41440-025-02249-1. Online ahead of print.PMID: 40537613

 

  1. Assessment of Burden of Partial Response to Standard Doses of Proton Pump Inhibitors in Patients with Clinically Diagnosed Gastroesophageal Reflux Disease: A Real-World Evidence Study in India. Garje Y, Saikia R, Gupta S, Peri S, Sharma P, Dharmadhikari S, Satpathy A, Khandhedia C, Markandeywar N, Mane A, Mehta S, Joglekar S.Drugs Real World Outcomes. 2025 Jun 19. doi: 10.1007/s40801-025-00497-8. Online ahead of print.PMID: 40537721

 

  1. Assessing large language models for acute heart failure classification and information extraction from French clinical notes. Bazoge A, Wargny M, Constant Dit Beaufils P, Morin E, Daille B, Gourraud PA, Hadjadj S.Comput Biol Med. 2025 Jun 19;195:110609. doi: 10.1016/j.compbiomed.2025.110609. Online ahead of print.PMID: 40541074

 

  1. Real-world effectiveness of MBA-VN vaccine against mpox, a test-negative case-control study. Escobar-Ziede P, Borras-Bermejo B, Pinós-Tella L, Vivet-Escalé M, Peñalver-Piñol A, Martinez J, Rodrigo-Pendás JÁ, García-Pérez J, Álvarez-López P, Nadal-Baron P, Antón A, Parés-Badell O. 2025 Jun 20;59:127295. doi: 10.1016/j.vaccine.2025.127295. Epub 2025 May 27.PMID: 40435852

 

  1. Long-Term Real-World Outcomes of Baricitinib in Severe Alopecia Areata: A 104-Week Retrospective Analysis From a Single Institute. Wada-Irimada M, Takahashi T, Sekine M, Okazaki T, Takahashi T, Chiba T, Yamazaki E, Shido K, Takahashi T, Mizuashi M, Asano Y.J Dermatol. 2025 Jun 20. doi: 10.1111/1346-8138.17829. Online ahead of print.PMID: 40539396

 

  1. Validation of an artificial intelligence-based algorithm for predictive performance and risk stratification of sepsis using real-world data from hospitalised patients: a prospective observational study. Kim JH, Lee K, Kim KJ, Ha EY, Kim IC, Park SH, Cho CH, Yu GI, Ahn BE, Jeong Y, Won JY, Sim T, Cho H, Lee KB.BMJ Health Care Inform. 2025 Jun 20;32(1):e101353. doi: 10.1136/bmjhci-2024-101353.PMID: 40541404

 

  1. Use of anthracyclines and trastuzumab for breast cancer in women with and without a history of cardiovascular disease in Sweden: a national cross-sectional study. Carreira H, Strongman H, Feychting M, Hubbert L, Hedayati E, Bidulka P, Matthews A, Bhaskaran K. 2025 Jun 20;11(1):56. doi: 10.1186/s40959-025-00356-z.PMID: 40542432 Free PMC article.

 

  1. Switching From Standard to Extended Half-Life Coagulation Factor Replacement in Haemophilia: Clinical Outcomes and Costs of Care in Finland. Koivusalo M, Szanto T, Kovalainen T, Vesikansa A, Laine O, Partanen A, Siitonen T, Vesanen M, Mehtälä J, Sarnesto N, Haapkylä J, Lehtinen AE, Lassila R. 2025 Jun 21. doi: 10.1111/hae.70067. Online ahead of print.PMID: 40542566